Avacta’s AVA6000 delivers 11.4-month PFS signal as investors await proof from lead drug AVA6103

Avacta Group plc (AIM: AVCT) has reported encouraging clinical data for faridoxorubicin (AVA6000), with median progression-free survival reaching 11.4 months in a selected subgroup of 32 patients with salivary gland cancer. Announced on 26 October 2026 during the European Society for Medical Oncology Congress in Madrid, the result compares with published historical benchmarks of six to 6.7 months and provides further human evidence supporting Avacta’s pre|CISION tumour-targeted drug delivery platform. The announcement also reported sustained drug activation over repeated treatment cycles, suggesting that the underlying delivery mechanism may remain active even as tumours shrink. However, the findings come from an early-stage, non-randomised study, while Avacta’s shares ended October at 60.5 pence, approximately 11% below the price of its latest equity fundraising, exposing the gap between promising clinical evidence and market confidence.

What do Avacta’s 11.4-month AVA6000 progression-free survival results actually show?

The latest data come from Avacta’s ongoing Phase 1a/1b study of faridoxorubicin, an experimental treatment designed to deliver the established chemotherapy drug doxorubicin more selectively into tumours. Across the study, 51 patients with salivary gland cancer received treatment at different dose levels, but the newly reported efficacy analysis concentrated on 32 patients meeting specified dose, disease-subtype and treatment-history criteria. The data cutoff was 5 October 2026, and the median progression-free survival of 11.4 months was accompanied by a 95% confidence interval extending from seven months to a median that could not yet be estimated at the upper boundary.

The efficacy findings included three partial responses and six additional minor tumour responses, with reported response durations ranging from 18.7 to 72 weeks. Three partial responses among 32 patients represent approximately 9.4% of the analysed group, while the minor responses indicate additional tumour shrinkage without meeting the threshold for a conventional partial response. Median overall survival had not been reached, meaning the study did not yet establish a mature overall-survival outcome. The combination of tumour shrinkage, sustained disease control and continued treatment in some patients provides an encouraging signal, although these measures describe different aspects of clinical activity.

Avacta compared the 11.4-month progression-free survival result with historical medians of six to 6.7 months, equivalent to an apparent improvement of approximately 70% to 90%. That comparison is useful for understanding the potential clinical significance of the finding, particularly in a rare cancer setting with limited therapeutic options. However, it does not establish that faridoxorubicin reduced the risk of progression by the same percentage, because patients were not randomly assigned to faridoxorubicin or a contemporary comparator treatment.

There is also an important difference between the populations being compared. Avacta’s conference poster identified 23 of the 32 patients in the efficacy subgroup as having adenoid cystic carcinoma, a salivary gland cancer that can follow a relatively prolonged disease course, whereas the cited 2025 historical review by Kanno and colleagues specifically examined salivary duct carcinoma. The study subgroup included 11 patients who had received no previous systemic therapy, adding another consideration when assessing comparisons across different treatment histories. More mature, histology-specific survival data and appropriately matched comparisons will be needed to determine how much of the observed disease control can be attributed to faridoxorubicin rather than differences in underlying tumour behaviour.

Why does sustained fibroblast activation protein activity strengthen the scientific case for Avacta’s pre|CISION platform?

Beyond the survival figures, Avacta’s latest announcement provides additional evidence about how its pre|CISION drug delivery system behaves during repeated treatment. The technology uses fibroblast activation protein, or FAP, an enzyme associated with cancer-related fibroblasts in the tumour microenvironment, to release the active chemotherapy payload from a peptide-drug conjugate. Its intended advantage is to increase exposure to the active drug within tumours while limiting unnecessary exposure in normal tissues, potentially improving the balance between anti-cancer activity and treatment-related toxicity.

Avacta reported that matched tumour biopsy and plasma measurements demonstrated a tumour-to-plasma concentration ratio of approximately 100:1 for released doxorubicin. These observations support the proposed localisation mechanism, although the measured ratio should not be interpreted as a universal concentration advantage across every patient or dose. The company also presented pharmacokinetic evidence of continued faridoxorubicin cleavage over as many as 12 treatment cycles, indicating that the delivery mechanism remained functional during prolonged administration in the patients assessed.

Another potentially significant finding came from FAP-targeted positron emission tomography imaging and tissue analysis. The data indicated that FAP-associated signals could persist even in patients whose tumours had substantially decreased in size, addressing the concern that a shrinking tumour might eventually lose the biological mechanism needed to activate further treatment. Preclinical experiments with Avacta’s next-generation technology suggested that treatment could recruit additional FAP-positive fibroblasts into the tumour environment, potentially sustaining the drug-release mechanism over time.

The clinical and preclinical evidence must nevertheless be distinguished. Human imaging and pharmacokinetic observations support persistent FAP activity, while the proposed mechanism involving recruitment of additional fibroblasts is supported more directly by experimental models. Demonstrating that persistent activation translates into superior long-term survival, lower treatment-limiting toxicity or better outcomes against established therapies will require additional clinical evidence.

How close is faridoxorubicin to a pivotal trial, and why does Avacta still need a commercial partner?

Avacta’s faridoxorubicin programme already has a clearer potential regulatory pathway than many early-stage oncology candidates. In June 2026, the company announced that it had reached agreement with the United States Food and Drug Administration on important elements of a single pivotal study in salivary gland cancer, with progression-free survival as the sole primary endpoint for a potential full approval application. The proposed population includes patients receiving first-line or second-line treatment in selected salivary gland cancer subtypes.

The October findings are relevant because they provide an initial progression-free survival signal in the disease setting that Avacta intends to pursue. Nevertheless, regulatory alignment on a trial design is not equivalent to regulatory approval, and the reported Phase 1 results do not replace the need for a successful pivotal study. The eventual trial will still need to demonstrate a convincing treatment effect in its defined population, supported by sufficiently robust safety and efficacy evidence.

Commercial strategy introduces another dependency. Avacta has indicated that it intends to advance faridoxorubicin into further clinical development with the support of a partner rather than independently financing the entire later-stage programme. This approach could limit direct development spending and preserve resources for its next-generation pipeline, although the economics would depend on the terms negotiated with a partner.

A licensing or development agreement might include upfront funding, development milestones, commercial royalties or shared development responsibilities, but no such financial structure should be assumed before an agreement is announced. For prospective partners, the October data offer additional biological and clinical evidence, while the remaining questions concern the strength of the proposed pivotal-trial design, the most commercially relevant cancer subtypes and the cost of generating registration-quality evidence.

Why could AVA6103 be more important to Avacta’s long-term valuation than the AVA6000 survival results?

Although faridoxorubicin generated the latest headline, Avacta’s principal internal development priority is AVA6103, a next-generation pre|CISION candidate carrying an exatecan payload. Exatecan belongs to the topoisomerase I inhibitor class, which has attracted significant oncology investment through antibody-drug conjugates. Avacta’s approach seeks to achieve controlled release of the payload in the tumour microenvironment using peptide-based chemistry rather than the antibody-targeting structure used by established antibody-drug conjugates.

The company began treating patients in its FOCUS-01 Phase 1 study in March 2026 following clearance of its investigational new drug application by the United States Food and Drug Administration. Subsequent preliminary data from the first three dose levels supported the intended controlled-release mechanism and showed a favourable initial tolerability profile. Avacta reported that the payload-equivalent exposure at the third dose level was approximately 50% higher than the maximum tolerated dose of conventional exatecan, although this cross-regimen comparison does not establish an equivalent improvement in patient outcomes.

At the European Society for Medical Oncology Congress, Avacta also presented experiments in gastric cancer models involving tumours previously exposed to trastuzumab deruxtecan, marketed as Enhertu by AstraZeneca and Daiichi Sankyo Company, Limited. In those preclinical models, AVA6103 demonstrated activity in tumours that had progressed following treatment with the established antibody-drug conjugate. The finding suggests a potential scientific route to treating certain resistant cancers, but results obtained in animal models cannot establish clinical superiority or an effective treatment option for patients whose cancers have become resistant.

The more consequential development will come when FOCUS-01 produces interpretable patient-level efficacy results. Avacta has indicated that additional tumour pharmacokinetic evidence is expected in late 2026 or early 2027, with initial efficacy data anticipated during the first half of 2027. These results will provide a direct test of whether the encouraging delivery mechanism can produce meaningful anti-tumour activity in patients, rather than merely confirming that the drug releases its payload as designed.

The company is also advancing AVA6207, a preclinical programme intended to deliver two therapeutic payloads through one FAP-mediated activation event. Management has targeted the fourth quarter of 2026 for announcing payload selection and supporting data for clinical candidate selection. This creates a broader platform opportunity, but AVA6207 remains at an earlier development stage and does not yet provide independent clinical validation of the dual-payload approach.

What does Avacta’s £12.5 million equity fundraising reveal about its financial flexibility?

Avacta’s financial position is an essential part of interpreting the oncology developments because the company is still principally a clinical-stage research business. Its interim results for the six months ended 30 June 2026 showed revenue from continuing operations of approximately £56,000, research expenditure of £9.69 million and an operating loss of £13.91 million. The loss from continuing operations after taxation reached £19.02 million, illustrating that current valuation depends predominantly on the future commercial potential of the development pipeline rather than established operating earnings.

Cash and cash equivalents stood at £20.27 million at the end of June but had declined to £10.59 million by 31 August. The company reported £15.69 million of cash outflow from operations and working capital movements during the first half, reflecting the substantial financial requirements of its research programmes. Those figures demonstrate the importance of external funding, although historical cash movements cannot be extrapolated mechanically into future monthly expenditure because development costs, financing and payment schedules fluctuate.

In October, Avacta raised gross proceeds of £12.5 million through an equity placing and subscription priced at 68 pence per share. The transaction involved approximately 18.38 million new ordinary shares, equivalent to about 3.9% of the previously issued share capital. Management indicated that the additional financing would extend the company’s expected cash runway into the second quarter of 2027, providing resources for continued work on AVA6103, faridoxorubicin and AVA6207.

Part of the fundraising was also allocated to existing financing obligations, with approximately £2.5 million earmarked for a convertible bond repayment scheduled for October. Avacta had reported an outstanding loan balance of £12 million as of 30 September, following earlier cash settlements of deferred bond payments. The October financing therefore served two purposes: supporting ongoing clinical development and managing obligations associated with the existing capital structure.

An extended runway provides Avacta with additional time to pursue clinical milestones and potential partnering agreements, but it does not eliminate future financing requirements. The company’s expected funding horizon extends into the same broad period as the anticipated AVA6103 efficacy readout, making the timing and quality of that evidence especially relevant to subsequent capital-raising negotiations. Any further equity financing would depend on prevailing market conditions, while licensing arrangements could potentially provide an alternative source of funding without necessarily removing all development commitments.

Why did Avacta shares finish October at 60.5p despite encouraging cancer trial results?

Avacta’s latest share-price performance presents a notable contrast with the company’s clinical announcements. The AIM-listed shares closed at 60.5 pence on 30 October 2026, compared with 63.3 pence on 23 October, a decline of approximately 4.4% over the five trading sessions that included the European Society for Medical Oncology presentation. The stock also declined about 16% during October, moving from 72 pence at the end of September.

The 60.5-pence closing price was approximately 11% below the 68-pence price of the October fundraising. This comparison does not prove why the shares declined, but it indicates that the newly issued equity had not established a lasting market-price floor. Investors were simultaneously assessing early clinical evidence, the company’s ongoing financing needs and the timing of more consequential trial results.

There is nevertheless a more optimistic institutional interpretation of Avacta’s prospects. In a research update dated 29 October, Trinity Delta assigned the company a risk-adjusted net present value estimate of £520 million, equivalent to approximately 106 pence per share, with a fully diluted estimate of 97 pence. Trinity Delta identifies Avacta as a corporate client, and its valuation reflects assumptions about future development, commercialisation and financing rather than a realised transaction value or a wider independent broker consensus.

The difference between that modelled valuation and the prevailing share price illustrates how strongly outcomes depend on the assumptions applied to the clinical pipeline. A favourable scenario could assign meaningful value to successful AVA6103 development, faridoxorubicin partnering and the potential for additional pre|CISION candidates. A more cautious scenario would place greater emphasis on unproven clinical efficacy, funding requirements and the possibility that encouraging early observations do not translate into commercially viable medicines.

The market’s subdued reaction should therefore not automatically be interpreted as a rejection of the underlying science. Avacta has strengthened the body of evidence supporting its drug delivery mechanism, but investors have not yet received mature, controlled efficacy results or a commercial partnership demonstrating the financial value of that technology. The latest trading performance suggests that the company still faces a substantial challenge in translating scientific progress into sustained equity-market confidence.

Which Avacta clinical and commercial milestones could materially change the investment case in 2027?

Avacta now has several distinct development milestones capable of testing different parts of its strategy. Additional AVA6103 tumour pharmacokinetic data should help establish whether the next-generation controlled-release mechanism behaves as expected within human tumours, while the first anticipated efficacy results during the first half of 2027 will address the more commercially consequential question of whether that mechanism produces meaningful clinical benefit. The forthcoming AVA6207 candidate-selection work will also indicate how quickly the company can translate its platform chemistry into additional development programmes.

For faridoxorubicin, attention will increasingly turn to the maturity of the progression-free survival dataset, evidence from individual salivary gland cancer subtypes and the status of potential development partnerships. The company’s agreement with the United States Food and Drug Administration on pivotal-trial design provides a defined regulatory objective, but progressing towards that trial will require sufficient financing, operational preparation and a suitable development strategy. A signed partnership with disclosed economics would provide a more measurable commercial validation than continued expressions of partnering interest.

Avacta has advanced beyond a purely preclinical platform proposition, with human evidence of tumour-associated drug release and early signs of anti-cancer activity. Yet its near-term financial position, mixed-histology survival comparisons and reliance on further clinical readouts prevent the latest announcement from resolving the wider investment case. The strongest evidence of progress would be a combination of convincing AVA6103 patient efficacy, a financially meaningful faridoxorubicin partnership and funding arrangements that support development beyond the company’s currently projected cash runway.

What should investors know about Avacta (AVCT) after its 11.4-month AVA6000 PFS result, £12.5 million raise and 16% October share decline?

– Avacta reported median progression-free survival of 11.4 months in a selected 32-patient salivary gland cancer subgroup treated with faridoxorubicin.

– Historical benchmarks of six to 6.7 months suggest a potentially meaningful signal, but differences in cancer subtypes and treatment populations limit direct comparisons.

– Three partial tumour responses and six minor responses were reported, while median overall survival had not been reached.

– Continued FAP activity and sustained doxorubicin release over repeated treatment cycles provide further evidence supporting Avacta’s pre|CISION delivery technology.

– The United States Food and Drug Administration has agreed on important elements of a potential pivotal trial design for AVA6000, but regulatory approval remains unachieved.

– AVA6103 is Avacta’s lead next-generation clinical programme, with initial patient efficacy data anticipated in the first half of 2027.

– The October £12.5 million fundraising extended management’s expected cash runway into the second quarter of 2027 while adding new shares to the capital structure.

– Avacta shares ended October at 60.5 pence, approximately 16% below their September closing level and 11% below the latest placing price.

– Further clinical validation, a commercially substantive partnership and sufficient funding beyond the current runway would provide measurable tests of the company’s longer-term strategy.